WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today ...
The Genentech Inc. unit of Roche AG announced that its Phase III (EMILIA) trial of Immunogen Inc.-partnered asset trastuzumab emtansine (T-DM1) showed positive results. Patients randomized to ...
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...
– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback